The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009; NCT02684032).
 
Andres Forero-Torres
Speakers' Bureau - Seagen
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst); TRACON Pharma (Inst)
 
Robert Wesolowski
Consulting or Advisory Role - Agenus; Nepa; Novartis
Research Funding - Acerta Pharma
Travel, Accommodations, Expenses - Agenus; Nepa; Novartis
 
Aditya Bardia
Consulting or Advisory Role - Genentech; Novartis
 
Haresh S. Jhangiani
No Relationships to Disclose
 
Peter Kabos
Research Funding - AstraZeneca (Inst); Lilly (Inst); Pfizer (Inst); Radius Health (Inst)
 
Elizabeth Claire Dees
No Relationships to Disclose
 
Kenneth Alan Kern
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Rachelle Perea
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Kristen J. Pierce
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Hope S. Rugo
Honoraria - Genomic Health
Speakers' Bureau - Genomic Health
Research Funding - Celsion (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Novartis; OBI Pharma; Pfizer; Roche/Genentech